日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

鼻用福鲁单抗治疗非活动性继发进展型多发性硬化症患者的疾病进展(与复发无关)

Sahyouni, Ronald; Mahmoodi, Amin; Mahmoodi, Amir; Rajaii, Ramin R; Hasjim, Bima J; Bustillo, David; Huang, Melissa; Tran, Diem Kieu; Chen, Jefferson W; Chitnis, Tanuja; Singhal, Tarun; Zurawski, Jonathan; Saraceno, Taylor J; Gopalakrishnan, Niveditha; Cain, Lauren; LaBarre, Brenna; King, Devin; Bergmark, Regan W; Maxfield, Alice Z; Cicero, Steven; Pan, Hong; Dubey, Shipra; Vaquerano, Steven; Hansel, Caleb; Healy, Brian C; Saxena, Shrishti; Lokhande, Hrishikesh A; Baharnoori, Moogeh; Madill, Evan Samuel; Sheth, Manali S; Rodin, Rachel; Ye, Jessica; Clementi, Nancy; Clementi, William A; Weiner, Howard L

Assessment of the impact of outcome definitions on power in multiple sclerosis clinical trials

评估结局定义对多发性硬化症临床试验效能的影响

Li, Cynthia X; Glanz, Bonnie I; Baharnoori, Moogeh; Healy, Brian C

Circadian rhythmicity of symptomatic phenotypes in multiple sclerosis: the CircaMS study protocol and feasibility of biomarker collection

多发性硬化症症状表型的昼夜节律性:CircaMS研究方案及生物标志物采集的可行性

Taccardi, Doriana; Gowdy, Hailey G M; Li, Vina Wenyu; Wing, Ana Cristina; Baharnoori, Moogeh; Finlayson, Marcia; Ghasemlou, Nader

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

加拿大使用奥法妥木单抗治疗复发缓解型多发性硬化症的成本效益分析

Bhan, Virender; Clift, Fraser; Baharnoori, Moogeh; Thomas, Kimberly; Patel, Barkha P; Blanchette, François; Adlard, Nicholas; Vudumula, Umakanth; Gudala, Kapil; Dutta, Nikkita; Grima, Daniel; Mouallif, Soukaïna; Farhane, Fatine

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort

在多发性硬化症患者队列中,富马酸二甲酯和干扰素疗效的比较

Sattarnezhad, Neda; Healy, Brian C; Baharnoori, Moogeh; Diaz-Cruz, Camilo; Stankiewicz, James; Weiner, Howard L; Chitnis, Tanuja

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

加拿大使用奥法妥木单抗治疗复发缓解型多发性硬化症的成本效益分析

Baharnoori, Moogeh; Bhan, Virender; Clift, Fraser; Thomas, Kimberly; Mouallif, Soukaïna; Adlard, Nicholas; Cooney, Philip; Blanchette, François; Patel, Barkha P; Grima, Daniel

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate

接受富马酸二甲酯治疗的多发性硬化症患者出现非致命性进行性多灶性白质脑病(PML)。

Baharnoori, Moogeh; Lyons, Jennifer; Dastagir, Akram; Koralnik, Igor; Stankiewicz, James M

The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions

第二届国际精神分裂症研究学会会议,2010年4月10日至14日,意大利佛罗伦萨:口头报告摘要

Baharnoori, Moogeh; Bartholomeusz, Cali; Boucher, Aurelie A; Buchy, Lisa; Chaddock, Christopher; Chiliza, Bonga; Föcking, Melanie; Fornito, Alex; Gallego, Juan A; Hori, Hiroaki; Huf, Gisele; Jabbar, Gul A; Kang, Shi Hyun; El Kissi, Yousri; Merchán-Naranjo, Jessica; Modinos, Gemma; Abdel-Fadeel, Nashaat A M; Neubeck, Anna-Karin; Ng, Hsiao Piau; Novak, Gabriela; Owolabi, Olasunmbo O; Prata, Diana P; Rao, Naren P; Riecansky, Igor; Smith, Darryl C; Souza, Renan P; Thienel, Renate; Trotman, Hanan D; Uchida, Hiroyuki; Woodberry, Kristen A; O'Shea, Anne; DeLisi, Lynn E